Genentech, Inc.
Clinical trials sponsored by Genentech, Inc., explained in plain language.
-
New drug aims to calm 'Fire' in hardened arteries
Disease control Not yet recruitingThis study is testing whether a new drug called selnoflast can reduce inflammation in the arteries of people with atherosclerosis (hardened arteries) who are at high risk for heart attacks or strokes. About 162 participants who are already on standard heart medications will recei…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
First human tests begin for new Vision-Saving eye injection
Disease control Not yet recruitingThis is an early-stage study to check the safety and how the body handles a new drug called RO7823653 for diabetic macular edema (DME), a cause of vision loss. About 93 people with DME will receive injections of the new drug into the eye, either by itself or alongside an existing…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
First human test for mystery drug begins
Knowledge-focused Not yet recruitingThis is the first study in humans for a new drug called RO7875913. It will be given to 40 healthy volunteers to check its safety, see how the body processes it, and find a safe dose for future studies. The goal is to gather information, not to treat any disease.
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:41 UTC